Dipeptidyl peptidase-IV (DPP-IV) inhibitors enhance the paracrine antilipolytic effects of neuropeptide Y (NPY)

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1607, 2007-01, pp. : 8-8

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Docking Study of Novel Pyrrolidine Derivatives as Potential Dipeptidyl Peptidase-IV (DPP-IV) Inhibitors

By  

Letters in Drug Design & Discovery, Vol. 12, Iss. 4, 2015-05 ,pp. : 284-291

Bentham Science Publishers

Access to resources Recommend Favorite

Sixteen-Years of Clinically Relevant Dipeptidyl Peptidase-IV (DPP-IV) Inhibitors for Treatment of Type-2 Diabetes: A Perspective

By  

Current Medicinal Chemistry, Vol. 21, Iss. 35, 2014-01 ,pp. : 4013-4045

Bentham Science Publishers

Access to resources Recommend Favorite

Azetidine-Based Inhibitors of Dipeptidyl Peptidase IV (DPP IV)

By  

Current Topics in Medicinal Chemistry, Vol. 7, Iss. 6, 2007-03 ,pp. : 597-608

Bentham Science Publishers

Access to resources Recommend Favorite

The Therapeutic Potential of Inhibitors of Dipeptidyl Peptidase IV (DPP IV) and Related Proline-Specific Dipeptidyl Aminopeptidases

By  

Current Medicinal Chemistry, Vol. 12, Iss. 8, 2005-04 ,pp. : 971-998

Bentham Science Publishers

Access to resources Recommend Favorite

Behavioral effects of neuropeptide Y in F344 rat substrains with a reduced dipeptidyl-peptidase IV activity

By Karl T.   Hoffmann T.   Pabst R.   von Horsten S.  

Pharmacology Biochemistry and Behavior, Vol. 75, Iss. 4, 2003-07 ,pp. : 869-879

Elsevier

Access to resources Recommend Favorite